Podium to Practice: EHA 2025 – Leukemia: EXPANSION

Podium to Practice: EHA 2025 – Leukemia: EXPANSION

Podium to Practice: EHA 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Julie Bergeron

Icon Chair Speaker

Speakers

Dr. Brian Leber

Dr. Danielle Hammond

Studies / Trials Discussed

S112 – SAFETY AND EFFICACY OF SINGLE-AGENT SUBCUTANEOUS BLINATUMOMAB IN ADULTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): RESULTS FROM A PHASE 1/2 DOSE EXPANSION STUDY

Studies/trials discussed:

S112 – SAFETY AND EFFICACY OF SINGLE-AGENT SUBCUTANEOUS BLINATUMOMAB IN ADULTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): RESULTS FROM A PHASE 1/2 DOSE EXPANSION STUDY
Tagged